课题基金 / 基金详情

Function of PCSK9 in LDLR and CD36 degradation: LDL cholesterol regulation and beyond.

Function of PCSK9 in LDLR and CD36 degradation: LDL cholesterol regulation and beyond.
PCSK9 在 LDLR 和 CD36 降解中的功能:LDL 胆固醇调节及其他。
批准号:
293225
负责人:
Mayer Gatan
金额:
$38.21万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-09-01 至 2017-09-01

项目摘要

项目成果

Mayer Gatan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cholesterol is a normal component of cells and is essential to the proper function of the human body. However, several factors such as heredity, obesity or an unhealthy diet can increase blood cholesterol levels, a major risk factor for heart diseases. Th
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical development of highly potent and orally bioavailable PCSK9 inhibitors for patients at high cardiovascular risk
  • 批准号:
    494266
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2023
  • 负责人:
    Mayer Gatan
  • 依托单位:
The PCSK9-induced degradation of cell surface receptors: LDL cholesterol regulation and beyond.
  • 批准号:
    274738
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2012
  • 负责人:
    Mayer Gatan
  • 依托单位:
Molecular characterization and inhibition of the PCSK9-assisted low-density lipoprotein receptor degradation pathway.
  • 批准号:
    231136
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2011
  • 负责人:
    Mayer Gatan
  • 依托单位:
Molecular characterization and inhibition of the PCSK9-assisted low-density lipoprotein receptor degradation pathway.
  • 批准号:
    215523
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2010
  • 负责人:
    Mayer Gatan
  • 依托单位:
海外基金